Anti-slamf7 chimeric antigen receptors
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsJames N. Kochenderfer, Steven A. Feldman
Life of this patent
Estimating the term…
Abstract
Provided are chimeric antigen receptors (CARs) having antigenic specificity for B-cell Maturation Antigen (SLAMF7). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.
Claims28
A nucleic acid comprising:
- (a) a suicide gene;
- and
- (b) a nucleotide sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen recognition domain, a transmembrane (TM) domain, and a T cell activation domain, and wherein the CAR has antigenic specificity for signaling lymphocyte activating molecule F7 (SLAMF7).
A CAR comprising an antigen recognition domain, a TM domain, and a T cell activation domain, wherein the CAR has antigenic specificity for SLAMF7, wherein the CAR does not comprise any of a Myc tag, an IgG4-Fc spacer, or an IgG4-Fc spacer which has been modified to prevent binding of an Fc receptor.
26-27. (canceled)
Dependencies are inferred from the claim text.